Jiangsu Hengrui Pharmaceuticals (01276) spent 19.9599 million yuan on January 30 to repurchase 343,100 A-shares.
Hengrui Medicine (01276) announced that on January 30, 2026, the company spent 1995.99 million yuan to repurchase 343,100 shares of A-shares at a repurchase price of 58.12-58.21 yuan per share.
Jiangsu Hengrui Pharmaceuticals (01276) announced that on January 30, 2026, the company will spend RMB 1995.99 million to repurchase 343,100 A shares at a repurchase price of RMB 58.12-58.21 per share.
Related Articles
DIGITAL DOMAIN (00547): Wang Weizhong Appointed as Non-Executive Director
CHINA EB LTD (00165): Completion of the issuance of the first tranche of medium-term notes in China for the year 2026.
CISI FIN (06058) attached purchase principal amount is 25.85 million Australian dollars notes.
DIGITAL DOMAIN (00547): Wang Weizhong Appointed as Non-Executive Director
CHINA EB LTD (00165): Completion of the issuance of the first tranche of medium-term notes in China for the year 2026.
CISI FIN (06058) attached purchase principal amount is 25.85 million Australian dollars notes.
RECOMMEND
Multiple A‑Share Companies Update Hong Kong IPO Progress Since Start Of Year
30/01/2026
Mainland Pharmaceutical Companies Rush To Hong Kong, Over 10 Firms Queue For IPO
30/01/2026
2026 Hong Kong Market Faces Unlocking Peak: HKD 1.6 Trillion In Restricted Shares To Be Released, How Will The Market Respond?
30/01/2026
